Qnexa complete response letter "manageable" says market as Vivus' stock rises
This article was originally published in Scrip
Vivus has received an expected complete response letter (CRL) from the US FDA turning down its lead product Qnexa (phentermine/topiramate), its closely watched investigational weight loss drug, because of safety concerns regarding potential teratogenic and cardiovascular risks that had been raised at an FDA advisory committee meeting in July.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.